Skip to main content
. 2022 Jul 29;12:944248. doi: 10.3389/fonc.2022.944248

Table 1-2.

Chemotherapy administered to ALL patients.

Diagnosis and Treatment ALL Patients (n = 15)
Diagnosis
ALL (HR)  11 (73.3%)
R/R ALL 4 (26.7%)
Chemical cycles
Consolidation 8 (53.3%)
Reinduction 3 (20.0%)
ALL-REZ BFM 2002 protocols 4 (26.7%)

ALL (HR), high risk of acute lymphoblastic luekemia; R/R ALL, relapsed and refractory acute lymphoblastic luekemia; ALL-REZ, Acute Lymphoblastic Leukemia-Relapse Study; BFM, Berlin-Frankfurt-Münster.